Shenxin Zeng

778 total citations
33 papers, 556 citations indexed

About

Shenxin Zeng is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Shenxin Zeng has authored 33 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 13 papers in Oncology and 13 papers in Hematology. Recurrent topics in Shenxin Zeng's work include Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (12 papers) and Ubiquitin and proteasome pathways (11 papers). Shenxin Zeng is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (12 papers) and Ubiquitin and proteasome pathways (11 papers). Shenxin Zeng collaborates with scholars based in China, Macao and Czechia. Shenxin Zeng's co-authors include Wenhai Huang, Zhengrong Shen, Zhimin Zhang, Xiaoliang Zheng, Jian Wang, Youlu Pan, Wenhai Huang, Mingfei Wu, X. K. Zhou and Xiaowu Dong and has published in prestigious journals such as Journal of Medicinal Chemistry, RSC Advances and European Journal of Medicinal Chemistry.

In The Last Decade

Shenxin Zeng

31 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shenxin Zeng China 13 429 215 138 88 30 33 556
Lata Chauhan United States 8 313 0.7× 159 0.7× 116 0.8× 50 0.6× 63 2.1× 15 489
Zhihao Liu China 15 438 1.0× 131 0.6× 53 0.4× 183 2.1× 26 0.9× 54 688
Marja Dubay United States 11 477 1.1× 168 0.8× 124 0.9× 43 0.5× 27 0.9× 14 567
Birgit Zech Germany 6 273 0.6× 108 0.5× 55 0.4× 94 1.1× 38 1.3× 7 427
Emanuela Capota United States 6 571 1.3× 152 0.7× 80 0.6× 91 1.0× 16 0.5× 8 688
Zhengnian Li United States 10 475 1.1× 207 1.0× 109 0.8× 54 0.6× 10 0.3× 16 592
Kathy A. Gelato Germany 14 739 1.7× 92 0.4× 135 1.0× 32 0.4× 19 0.6× 21 815
Christelle Gasser Switzerland 6 346 0.8× 243 1.1× 114 0.8× 207 2.4× 8 0.3× 6 674
Bo‐Tao Xin Netherlands 13 395 0.9× 159 0.7× 56 0.4× 145 1.6× 44 1.5× 20 492
Maria Goralski United States 4 599 1.4× 175 0.8× 92 0.7× 51 0.6× 12 0.4× 4 684

Countries citing papers authored by Shenxin Zeng

Since Specialization
Citations

This map shows the geographic impact of Shenxin Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenxin Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenxin Zeng more than expected).

Fields of papers citing papers by Shenxin Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shenxin Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenxin Zeng. The network helps show where Shenxin Zeng may publish in the future.

Co-authorship network of co-authors of Shenxin Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Shenxin Zeng. A scholar is included among the top collaborators of Shenxin Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shenxin Zeng. Shenxin Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Zihan, et al.. (2025). A double-edged sword of neo-substrate degradation in PROTACs. European Journal of Medicinal Chemistry. 301. 118253–118253.
2.
Wu, Mingfei, Shenxin Zeng, Yong Chen, et al.. (2025). Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK Degradation. Journal of Medicinal Chemistry. 68(11). 10800–10822. 2 indexed citations
3.
Wang, Shu, et al.. (2024). Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations. Chemico-Biological Interactions. 403. 111241–111241. 1 indexed citations
4.
Wu, Mingfei, Wei Wang, Tao Liu, et al.. (2024). Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML. European Journal of Medicinal Chemistry. 275. 116539–116539. 5 indexed citations
5.
Zeng, Ming, et al.. (2024). Design, synthesis, and pharmacological evaluation of triazine-based PI3K/mTOR inhibitors for the potential treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry. 284. 117200–117200. 2 indexed citations
6.
Zeng, Shenxin, Mingfei Wu, Xinyi Chen, et al.. (2024). Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody. European Journal of Medicinal Chemistry. 267. 116206–116206. 9 indexed citations
7.
Wu, Mingfei, Yanhong Wang, Jingyu Zhang, et al.. (2023). Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorganic Chemistry. 142. 106952–106952. 14 indexed citations
8.
Pan, Youlu, et al.. (2023). The progress of molecules and strategies for the treatment of HBV infection. Frontiers in Cellular and Infection Microbiology. 13. 1128807–1128807. 28 indexed citations
9.
Zeng, Shenxin, Ming Zeng, Jian‐Dong Huang, et al.. (2023). Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion. Bioorganic Chemistry. 139. 106728–106728. 8 indexed citations
10.
Zhang, Jingyu, Mingfei Wu, Shenxin Zeng, et al.. (2023). Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia. European Journal of Medicinal Chemistry. 262. 115872–115872. 10 indexed citations
11.
Zeng, Shenxin, et al.. (2023). Current advances and development strategies of orally bioavailable PROTACs. European Journal of Medicinal Chemistry. 261. 115793–115793. 47 indexed citations
12.
Zeng, Shenxin, et al.. (2023). Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling. Bioorganic Chemistry. 143. 107016–107016. 12 indexed citations
13.
Pan, Youlu, et al.. (2022). The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. European Journal of Medicinal Chemistry. 238. 114442–114442. 20 indexed citations
14.
Zeng, Ming, et al.. (2022). Direct α-methylenation of triazines to terminal olefins with DMA. New Journal of Chemistry. 46(42). 20065–20068. 3 indexed citations
15.
Wang, Jian, et al.. (2021). An efficient and practical aerobic oxidation of benzylic methylenes by recyclable N-hydroxyimide. RSC Advances. 11(5). 3003–3011. 12 indexed citations
16.
Zeng, Shenxin, Dongmei Yan, Linglan Tu, et al.. (2021). Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression. Leukemia Research. 109. 106649–106649. 2 indexed citations
17.
Zeng, Shenxin, Hongjie Zhang, Zhengrong Shen, & Wenhai Huang. (2021). Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. Frontiers in Chemistry. 9. 639176–639176. 21 indexed citations
18.
Zeng, Shenxin, Wenhai Huang, Xiaoliang Zheng, et al.. (2020). Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. European Journal of Medicinal Chemistry. 210. 112981–112981. 180 indexed citations
19.
Huang, Wenhai, Shu Wang, Zhimin Zhang, et al.. (2020). HZ-A-005, a potent, selective, and covalent Bruton’s tyrosine kinase inhibitor in preclinical development. Bioorganic Chemistry. 105. 104377–104377. 6 indexed citations
20.
Zhi, Yanle, Shu Wang, Wenhai Huang, et al.. (2019). Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation. European Journal of Medicinal Chemistry. 179. 502–514. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lata Chauhan Breakdown of academic impact, for papers by Zhihao Liu Breakdown of academic impact, for papers by Marja Dubay Breakdown of academic impact, for papers by Birgit Zech Breakdown of academic impact, for papers by Emanuela Capota Breakdown of academic impact, for papers by Zhengnian Li Breakdown of academic impact, for papers by Kathy A. Gelato Breakdown of academic impact, for papers by Christelle Gasser Breakdown of academic impact, for papers by Bo‐Tao Xin Breakdown of academic impact, for papers by Maria Goralski
Rankless by CCL
2026